🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07809620
Recruiting Observational

Preoperative Predictors of Symptom Improvement After Laparoscopic Fundoplication

NCT07809620 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-09-20
Last updated
2026-09-22

Condition(s) studied

Gastroesophageal Reflux DiseaseHiatal HerniaEsophagitis, PepticBarrett Esophagus

Investigational drug(s) / intervention(s)

Laparoscopic Nissen fundoplicationLaparoscopic Toupet fundoplication

Laparoscopic Nissen fundoplication: Standardized laparoscopic complete 360-degree fundoplication with complete hiatal dissection, preservation of the vagi, circumferential mobilization of the distal esophagus to at least 2.5 cm of tension-free intra-abdominal length, posterior crural approximation, and division of short gastric vessels as required. Performed as part of routine clinical care and observed by the study.

Laparoscopic Toupet fundoplication: Standardized laparoscopic posterior partial 270-degree fundoplication using the same hiatal dissection and esophageal mobilization as for the complete wrap. Performed as part of routine clinical care and observed by the study.

Study summary

Laparoscopic fundoplication is the standard operation for gastroesophageal reflux disease (GERD) that does not respond adequately to medication, and it relieves reflux symptoms in most patients who are carefully selected for it. Even so, published studies consistently report that between 10% and 30% of patients continue to have symptoms afterwards, develop troublesome side effects such as difficulty swallowing or bloating, or are dissatisfied with the result. Much of this disappointment reflects who was chosen for surgery rather than any technical fault in the operation: patients whose symptoms are not actually caused by acid reflux predictably gain little benefit from a well-constructed wrap.

Individual factors measured before surgery, such as the amount of acid in the esophagus, the link between symptoms and reflux episodes, the type of symptoms, and how well the patient responded to acid-suppressing tablets, have each been linked to the outcome. However, most of that evidence comes from retrospective studies that used different definitions of success, so it is still unclear which factors matter independently once they are considered together.

This study will follow adults with objectively confirmed GERD who are scheduled for elective laparoscopic fundoplication at Minia University Hospitals. Before surgery, every participant undergoes the same standardized assessment: upper endoscopy, 24-hour pH-impedance monitoring off acid-suppressing medication, high-resolution manometry, measurement of height and weight, and questionnaires covering reflux symptoms, anxiety, depression and physical symptom burden. Participants then complete validated symptom questionnaires again at 1, 3, 6 and 12 months after the operation.

The main measure of success is "responder status" at 12 months, meaning at least a 50% improvement in the total GERD-HRQL symptom score compared with before surgery, supported by the patient's own rating of satisfaction. The investigators will analyze ten factors recorded before surgery to determine which of them independently predict this outcome, and will use the results to build and test a prediction tool that surgeons can apply during preoperative counseling.

The study does not assign any treatment. The type of wrap performed, either a complete (Nissen) or a partial posterior (Toupet) fundoplication, is chosen by the treating surgeon according to a prespecified rule based on esophageal motility, exactly as in routine practice. Taking part involves completing questionnaires and attending the usual follow-up appointments, and adds no additional procedural risk.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years or older. * Objectively documented gastroesophageal reflux disease, defined by at least one of the following: pathological acid exposure on off-PPI 24-hour pH or pH-impedance monitoring; Los Angeles grade C or D esophagitis; biopsy-proven Barrett's esophagus; or a positive symptom-reflux association. * Medically refractory or PPI-dependent disease, troublesome regurgitation, or a symptomatic hiatal hernia, with an elective decision for laparoscopic fundoplication. * Able to provide written informed consent and to complete the study questionnaires. Exclusion Criteria: * Previous antireflux or other major foregut or esophagogastric surgery. * Achalasia or a major esophageal motility disorder on high-resolution manometry (Chicago Classification version 4.0): absent contractility, esophagogastric junction outflow obstruction, distal esophageal spasm, or hypercontractile esophagus. * Giant or complex paraesophageal hernia requiring non-standard reconstruction, or a concurrent bariatric or other major intra-abdominal procedure. * Esophageal or gastric malignancy. * Emergency surgery. * Pregnancy. * Inability to complete patient-reported outcome instruments or to attend follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Minia University Hospitals - Department of Surgery, Faculty of Medicine, Minia University Minya Minya Governorate Recruiting

More Minia University trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07809620 on ClinicalTrials.gov ↗ ← All trials in Egypt